manuscript preparation. Author Contributions Conceptualization: Elizabeth Muir. Data curation: Elizabeth Muir, Clare Ellis, Emily Burnside, Fiona Love, Simon Heller, Matthew Elliot, Esther Daniell, Debayan ... Dasgupta, Nuno Alves, Priscilla Day. Formal analysis: Elizabeth Muir, Mansoor Raza, Emily Burnside, Fiona Love, Simon Heller, Matthew Elliot, Esther Daniell, Debayan Dasgupta, Nuno Alves, Priscilla Day
Aims/hypothesis The double-blind Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) assessed the cardiovascular safety of insulin degludec. The incidence and rates of adjudicated severe hypoglycaemia, and all-cause mortality were also determined. This paper reports a...
A/S. Simon Heller has served as a consultant to Novo Nordisk, Eli Lilly, Sanofi, Boehringer– Ingelheim and Takeda, served on the speaker panel of Novo Nordisk, Eli Lilly, Sanofi, MSD, and Takeda, and
Aims/hypothesis Intensive glucose control reduces the risk of vascular complications while increasing the risk of severe hypoglycaemia at a group level. We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes. Methods We performed a post hoc analysis of the Action in Diabetes and Vascular Disease: Preterax and...
Background The perspectives and experiences of trial staff are increasingly being investigated as these can be used to improve recruitment, adherence to trial protocols and support given to future staff. We interviewed staff working on a type 1 diabetes trial in order to aid interpretation of trial findings, inform recommendations for the rollout of the treatments investigated...
Stephen Harrap Simon Heller Stephen MacMahon Giuseppe Mancia Michel Marre David Matthews Bruce Neal Neil Poulter Anthony Rodgers Bryan Williams Sophia Zoungas for the ADVANCE-ON Collaborative Group
. Evans,2 Roman Hovorka,2 Simon Heller,3 Desmond G. Johnston,1 Stephanie A. Amiel,4 and Katharine Barnard5 To effectively develop future diabetes technologies that meet these standards, robust and
lecture fees from Novo Nordisk, AstraZeneca, Bristol-Myers Squibb and Eli Lilly. Simon Heller has received: consulting fees from Abbott, Amylin, AstraZeneca, Eli Lilly, Johnson and Johnson, Mannkind, Novo
OBJECTIVE This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas).
OBJECTIVE To develop and pilot a novel intervention addressing motivational and cognitive barriers to avoiding hypoglycemia in people with type 1 diabetes and persistent impaired awareness of hypoglycemia (IAH) despite training in flexible insulin therapy.
OBJECTIVE DAFNE (Dose Adjustment For Normal Eating), a structured education program in flexible insulin therapy, has been widely adopted in the U.K. after validation in a randomized trial. To determine benefits in routine practice, we collected biomedical and psychological data from all participants attending during a 12-month period.
Aims/hypothesis Data are inconsistent regarding the associations between age, age at diagnosis of diabetes, diabetes duration and subsequent vascular complications. Methods The associations between age (or age at diagnosis), diabetes duration and major macrovascular events, all-cause death and major microvascular events were examined in 11,140 patients with type 2 diabetes...
OBJECTIVE To determine whether improvements in glycemic control and diabetes-specific quality of life (QoL) scores reported in research studies for the type 1 diabetes structured education program Dose Adjustment For Normal Eating (DAFNE) are also found when the intervention is delivered within routine U.K. health care.
DEBBIE COOKE PHD MARY CLARE O'HARA MSC NAOMI BEINART MSC SIMON HELLER DM ROBERTO LA MARCA PHD MOLLY BYRNE PHD PETER MANSELL DM DPHIL OBJECTIVEdTo develop a linguistically and psychometrically
MARK WOODWARD PHD ANUSHKA PATEL PHD SOPHIA ZOUNGAS PHD LISHENG LIU CHANGYU PAN NEIL POULTER ANDRZEJ JANUSZEWICZ NIKHIL TANDON PHD PRASHANT JOSHI SIMON HELLER BRUCE NEAL PHD JOHN CHALMERS PHD
Kamlesh Khunti 2 Melanie J Davies Simon Heller 0 Diabetes Research Department, University Hospitals of Leicester NHS Trust , Leicester , UK 1 AHP Research , Hornchurch , UK/The Australian Centre for 2
SIMON HELLER PETER DAMM DMSC HENRIETTE MERSEBACH PHD TRINE VANG SKJTH RISTO KAAJA PHD MOSHE HOD SANTIAGO DUR AN-GARCA PHD DAVID MCCANCE ELISABETH R. MATHIESEN DMSC OBJECTIVE - A recent randomized
SOPHIA ZOUNGAS PHD BASTIAAN E. DE GALAN PHD TOSHIHARU NINOMIYA PHD DIEDERICK GROBBEE PHD PAVEL HAMET PHD SIMON HELLER STEPHEN MACMAHON DSC PHD OBJECTIVE To assess the magnitude and independence of
OBJECTIVE—To assess the safety and efficacy of insulin aspart (IAsp) versus regular human insulin (HI) in basal-bolus therapy with NPH insulin in pregnant women with type 1 diabetes. RESEARCH DESIGN AND METHODS—Subjects (n = 322) who were pregnant or planning pregnancy were randomized to IAsp or HI as meal-time insulin in an open-label, parallel-group, multicenter study. Subjects...